Products and methods for treating autoimmune diseases

A novel CD19-specific CAR T-cell therapy with optimized CDR sequences addresses the limitations of current treatments by enhancing B-cell depletion and reducing toxicity, providing a safer and more effective treatment for autoimmune diseases like SLE.

JP2026537416APending Publication Date: 2026-11-09AUTOLUS LIMIED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026523844
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-09-26
Filing Date
2024-10-22
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Current treatments for autoimmune diseases like systemic lupus erythematosus (SLE) are limited by significant side effects and the need for continuous therapy, with CD19-targeted CAR T-cell therapy facing challenges such as cytokine release syndrome, neurotoxicity, and T-cell exhaustion, making alternative CARs necessary.

Method used

A novel CD19-specific chimeric antigen receptor (CAR) with specific CDR sequences (GYAFSSS, YPGDED, SLLYGDYLDY, SASSSVSYMH, DTSKLAS, QQWNINPLT) is used to engineer T or NK cells for targeted B-cell depletion, reducing toxicity and enhancing persistence and efficacy.

Benefits of technology

The novel CAR T cells effectively deplete autoreactive B cells, reducing disease symptoms and maintaining remission in SLE patients with lower cytokine release and T-cell exhaustion, offering a safer and more durable treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026537416000050
    Figure 2026537416000050
  • Figure 2026537416000051
    Figure 2026537416000051
  • Figure 2026537416000001
    Figure 2026537416000001
Patent Text Reader

Abstract

The present invention relates to a chimeric antigen receptor (CAR) that binds to the B lymphocyte antigen CD19 (differentiation antigen group 19), and further relates to the use of T cells expressing such CARs for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). The present invention relates to a chimeric antigen receptor (CAR) that binds to the B lymphocyte antigen CD19 (differentiation antigen group 19), and further relates to the use of cytolytic cells expressing such CARs for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Field of Invention The present invention relates to a chimeric antigen receptor (CAR) that binds to the B lymphocyte antigen CD19 (differentiation antigen group 19), and more particularly to the use of cytolytic cells expressing the CAR for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). [Background technology]

[0002] background B cells, along with T cells, form the core of the adaptive arm of the immune system and play a major role in regulating immune responses in both normal physiological and pathological conditions. B cells are identified as pharmacological targets in B-cell malignancies and autoimmune diseases.

[0003] autoimmune disease Numerous diseases are thought to be caused by autoimmune mechanisms. Among the most common are rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, scleroderma, vasculitis, and pemphigus vulgaris. Millions of individuals worldwide suffer from autoimmune diseases, and the cost of these diseases, in terms of actual treatment expenditures and lost productivity, is estimated at billions of dollars annually.

[0004] Systemic lupus erythematosus Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex-mediated inflammation, and organ damage, including the skin, joints, central nervous system, heart, lungs, and kidneys (Tsokos GC. (2011). Systemic lupus erythematosus. N Engl J Med 365(22):2110-21; Kaul A, Gordon C, Crow M, et al. (2016). Systemic lupus erythematosus. Nature Reviews 2:1-21; Mackensen A, Muller F, Mouglakakos D, et al. (2022). Anti-CD19 CAR T cell therapy for refractory lupus erythematosus. Nature Medicine 28:2124-2132). It is a genetically complex disease exhibiting genetic heterogeneity (Kaul et al, above). Due to the vast variability in clinical and serological symptoms, SLE is a highly heterogeneous disease. Disease severity also changes over time, with alternating periods of disease inactivity and periods of disease relapse / relapse. In addition to this heterogeneity, SLE can be complicated by comorbidities such as infections, early-onset atherosclerosis and chronic organ damage, as well as subjective symptoms including reduced quality of life. Disease onset generally occurs between the ages of 20 and 40, and it primarily affects young women. People with SLE have approximately three times the mortality risk of the general population.

[0005] Currently available treatments aim to reduce inflammation, manage symptoms, and prevent organ damage, but they have significant side effects that raise safety concerns. Long-lasting complete remission, without serological or clinical disease activity, as well as a state free from glucocorticoids and immunosuppressants, is rarely achieved. Therefore, the medical need for potentially curative treatments with a better safety profile and a convenient interval of no treatment required, particularly for severely refractory patients, remains unmet.

[0006] Autoreactive B cells, which form autoantibodies, play a major role in the pathogenesis of SLE (Mackensen et al., see above). However, B-cell depletion agents such as rituximab, an anti-CD20 antibody, did not improve clinical outcomes compared to placebo in randomized studies of SLE and lupus nephritis (LN) (Merrill J, Neuwelt CM, Wallace DJ, Shanahan JC, et al. (2010). Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II / III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222-33; Rovin et al., (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum 64(4): 1215-26) However, two different biologics have recently been approved for SLE: belimumab, an anti-BAFF / BLyS monoclonal antibody, has been approved as an add-on therapy for adult patients with active autoantibody-positive SLE who have high disease activity despite receiving standard therapy (Benlysta (belimumab) USPI. 2023. Available at: gskpro.com / content / dam / global / hcpportal / en_US / Prescribing_Information / Benlysta / pdf / BENLYSTA-PI-MG-IFU.PDF. Last accessed August 25, 2023; Benlysta (belimumab) SmPC. 2023.Available at: www.ema.europa.eu / en / documents / product-information / benlysta-epar-product-information_en.pdf (Last accessed August 30, 2023). Aniflorumab, a type I interferon (IFN) receptor antagonist, is also approved in the US and EU and is indicated as an add-on for the treatment of adult patients with moderate to severe SLE receiving standard therapy (Saphnelo (aniflorumab-fnia) USPI, 2022). Available at: www.den8dhaj6zs0e.cloudfront.net / 50fd68b9-106b-4550-b5d0-12b045f8b184 / 44b6985c-8268-46b1-ba3 e-2bb43bfd4d4c / 44b6985c-8268-46b1-ba3e-2bb43bfd4d4c_viewable_rendition__v.pdf. Last accessed August 25, 2023; Saphnelo (aniflorumab-fnia) SmPC. 2022. Available at: www.ema.europa.eu / en / documents / product-information / saphnelo-epar-product-information_en.pdf. (Last accessed August 25, 2023). In addition, voclosporine (Lupkynis, USPI, 2021) was approved for lupus nephritis based on the AURORA1 trial (Rovin et al., Lancet 2021) (www.doi.org / 10.1016 / S0140-6736(21)00578-X). Voclosporine in combination with MMF and low-dose steroids resulted in clinically and statistically superior complete renal response rates with a comparable safety profile compared to MMF and low-dose steroids alone. Despite these approvals, some patients exhibit inadequate response, lack of response, or persistent lack of response and are at risk of further organ damage despite receiving standard therapy. Therefore, challenges remain regarding treatment-resistant disease.

[0007] Another strategy for inducing more profound depletion of B cell compartments originates from the highly effective treatment of patients with B cell malignancies using chimeric antigen receptor (CAR) T cells targeting CD19 (Cappell KM, Kochenderfer JN. (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Review 20:359-371). Several CD19-targeted CAR T cells are currently approved for relapsed and / or refractory B cell lymphoma as well as B-cell acute lymphoblastic leukemia (B-ALL) (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel). Long-term follow-up data indicate that CD19-targeted CAR T cells may be curative for a subset of patients with B cell lymphoma and possibly B-ALL (Cappell and Kochenderfer, supra; Westin J, Davis RE, Feng L, Hagemeister F, et al. (2023). Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol 41(4):745-55).

[0008] Two preclinical studies in lupus-prone mice support the efficacy of CD19 CAR T cells in SLE. After administration of CD19-targeted CAR T cells (1D3 CAR and FMC63 CAR), B cells in such mice were depleted, autoantibody production was interrupted, and glomerulonephritis and other organ manifestations were reversed.

[0009] Using autoimmune New Zealand cross mice (NZB×NZW) F1 and Murphys Roths Large (MRL) fas / fas mice, lupus models were used to identify CD8 cells expressing a CD19-targeting CAR [1D3 CAR (Kochenderfer JN, Yu Z, Frasheri D, et al. (2010), Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116(19), 3875-3886)]. + T cells are CD19 + Sustained B cell depletion by CD19-targeted CAR T cells has been shown to eliminate autoantibody production, improve disease symptoms in target organs, and extend lifespan far beyond the normal range in these autoimmune mouse models (Kansal R, Richardson N Neeli I, et al. (2019). Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11(482): eaav1648-eaav1648). CAR T cells have been present in vivo for one year and are CD44 + CD62L + Central Memory CD8 + Significant enrichment was observed in a subset of T cells, suggesting that this population may possess CAR and contribute to persistent B cell depletion. Kansel et al. showed that adoptive transfer of splenic T cells from CAR T cell-treated mice increased CD19 in naive autoimmune mice. + The study demonstrated that depleting B cells reduced disease, indicating that disease control was cell-mediated.

[0010] Using a constructed mouse anti-CD19 CAR [1D3 CAR (Kochenderfer et al., 2010, supra)] having either CD28 or 4-1BB as an intracellular co-stimulatory motif, Jin et al (Jin X, Xu Q, Pu C, Zhu K, et al. (2021). Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896-1903) evaluated the therapeutic function of the corresponding CAR-T cells by injecting them into a lupus mouse model (MRL-lpr). Anti-CD19 CAR T cells transferred to MRL-lpr mice at disease onset were evaluated to determine their role in SLE prevention. Compared with antibody treatment, adoptive transfer of the constructed anti-CD19 CAR-T cells showed a more sustained B cell depletion effect in MRL-lpr mice. Transfer of syngeneic anti-CD19 CAR-T cells not only prevented the disease pathogenesis before the onset of disease symptoms, but also presented therapeutic benefits at a later stage after disease progression. CAR-T cells with the 4-1BB co-stimulatory motif showed superior therapeutic efficiency without cell enrichment, compared with CAR-T cells with the CD28 co-stimulatory motif.

[0011] In summary, these two preclinical results indicate that anti-CD19 CAR-T cell therapy was effective in prevention and treatment, albeit in a mouse model of SLE.

[0012] Recently, belimumab, an anti-B cell activating factor (BAFF) / B lymphocyte stimulator (BlyS) monoclonal antibody, has been approved as an add-on therapy in adult patients with active autoantibody-positive SLE receiving standard therapy (Benlysta USPI, supra).

[0013] Tolerability and efficacy were first examined in a single SLE patient treated with CD19 CAR (FMC63 CAR) (Mougiakakos D, Kronke G, Volkl S, Kretschmann S, et al. (2021). CD-19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567-9). The same research group further evaluated the tolerability and efficacy of CD19 CAR T cell therapy (FMC63 CAR) in a small series of severe and treatment-resistant SLE patients (Mackensen et al, see above). In this series of patients, autologous T cells derived from five SLE patients were transduced with a lentiviral anti-CD19 CAR vector, expanded, and returned to the patients at a rate of 1 × 10⁶ cells per kg of body weight after lymphocyte depletion with fludarabine and cyclophosphamide. 6 The CAR T cells were reinfused at a dose of [number] cells. The CAR T cells expanded in vivo, resulting in deep B cell depletion and normalization of laboratory parameters, including improvement in clinical symptoms and seroconversion of anti-ds DNA antibodies. SLE remission according to DORIS criteria was achieved in all five patients after 3 months, and drug-free remission was maintained during longer follow-up after CAR T cell administration.

[0014] Recent case evidence of CD19-targeted CAR T cell therapy (FMC63 CAR) in other autoimmune diseases has been demonstrated in patients with refractory idiopathic inflammatory myopathy associated with antisynthetase syndrome (Muller F, Boeltz S, Knitza J, Aigner M, et al. (2023). CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401(10379):815-8; Percher AC, Hensen L, Klein R, et al. (2023). CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154-62).

[0015] Chimeric antigen receptor Traditionally, antigen-specific T cells have been generated by selectively expanding peripheral blood T cells that are naturally specific to the target antigen. However, selectively expanding a large number of T cells specific to most cancer antigens is difficult, and often impossible. Gene therapy using embedded vectors offers a solution to this problem: transgenic expression of chimeric antigen receptors (CARs) allows for the easy generation of a large number of T cells specific to any surface antigen by ex vivo viral vector transduction of a mixed population of peripheral blood T cells.

[0016] The most common form of such molecules is a fusion of a single-strand variable fragment (scFv) derived from a monoclonal antibody that recognizes a target antigen, fused to a signaling end domain via a spacer and transmembrane domain. Such molecules result in T cell activation in response to the recognition of their cognitive target by the scFv. When T cells express such a CAR, they recognize and kill target cells expressing the target antigen. Several CARs have been developed for tumor-associated antigens, and adoptive transfer approaches using such CAR-expressing T cells are currently in clinical trials for the treatment of various cancers. However, to date, the primary clinical exploration and potential application of CAR therapy has been as a treatment for B-cell malignancies.

[0017] CAR for CD19 CD19 is a B-cell antigen that is expressed very early in B-cell differentiation and disappears only at the final stage of B-cell differentiation into plasma cells. Therefore, CD19 is expressed in all B-cell malignancies except multiple myeloma. CD19 is not expressed in other hematopoietic populations or in non-hematopoietic cells, and therefore, targeting this antigen should not cause toxicity to the bone marrow or non-hematopoietic organs. Effective CD19 CAR T-cell therapy results in B-cell aplasia, but the resulting hypogammaglobulinemia can be treated with pooled immunoglobulins, so the loss of a normal B-cell compartment is considered an acceptable toxicity when treating lymphoid malignancies.

[0018] Therefore, CD19 is an attractive CAR target. To date, the main clinical focus in the CAR field has been on research targeting CD19 in refractory B-cell cancer, as summarized in Table 1.

[0019] Various CAR designs have been tested for CD19 in various facilities, as outlined in Table 1. [Table 1] The majority of research has examined CD19 CARs (i.e., CD19-targeting CARs) based on scFv derived from the hybridoma fmc63. The most promising applications have been in the treatment of acute lymphoblastic leukemia (ALL).

[0020] Immunotoxicity of CD19 CAR therapy Cytokine release syndrome (CRS) encompasses a range of inflammatory symptoms, from mild to multiple organ failure accompanied by hypotension and respiratory failure. Some degree of CRS is common in patients treated with CD19 CAR T cells. In recent cohorts, approximately 30% (21 / 73) of treated patients showed some degree of CRS (Davila et al ((2014). Sci. Transl. Med. 6, 224ra25; Lee et al (2014) Lancet. doi:10.1016 / S0140-6736(14)61403-3; Kochenderfer et al. (2014) J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., doi:10.1200 / JCO.2014.56.2025). CRS was also observed in patients treated with blinatumomab, a bispecific recombinant single-chain antibody that recognizes both CD19 and CD3. CRS typically occurs 5–21 days after CAR T cell infusion.

[0021] CRS can be life-threatening and requires treatment in an intensive care setting. CRS is accompanied by elevated serum cytokine levels. The most significantly elevated cytokines are IL-6, IL-10, and interferon-gamma (IFNγ). The clinical manifestations of severe CRS (fever, hepatosplenomegaly, coagulation disorders, and hyperferritinemia) are similar to those of macrophage activation syndrome (MAS), found, for example, in patients with congenital T cell defects. This suggests the involvement of general immunopathological processes. Currently, it is unclear which cell types (CAR T cells, dysty tumor cells, or locally activated macrophages) are responsible for the production of major cytokines (particularly IL-6). However, a major initiating factor in MAS is the release of large amounts of interferon-gamma (Lopez-Alvarez et al. (2009). Clin. Vaccine Immunol. CVI 16, 142-145).

[0022] Neurotoxicity In a multicenter CD19 CAR study, several patients developed transient neurotoxicity with varying degrees of severity, ranging from aphasia to blunting, delirium, and epileptic seizures (Davilia et al., see above). This appears to be limited to ALL patients, and similar syndromes have been described after blinatumomab therapy. Brain imaging appears normal. Neurotoxicity may reflect high levels of systemic cytokines crossing the blood-brain barrier.

[0023] Persistent, relapsing, and T-cell exhaustion A prolonged response appeared to correlate with higher peak levels of circulating CAR-transduced T cells, as well as the duration of B cell aplasia. Except for patients with relapsed CD19 disease, relapses were generally associated with loss of circulating CAR T cells and recovery of normal B cells.

[0024] T-cell exhaustion is a state of T-cell dysfunction that occurs during many chronic infections and cancers. It is defined by insufficient effector function, persistent expression of inhibitory receptors, and a transcriptional state different from both functional effector T cells and memory T cells. Exhaustion impairs the optimal control of infections and tumors. In recent years, a clearer picture of the functional and phenotypic profiles of exhausted T cells has emerged, with the expression of the inhibitory receptor programmed death 1 (PD-1; also known as PDCD1), a negative regulator of activated T cells, being a major characteristic (Day et al. (2006) Nature 443, 350-354).

[0025] Responses in CD19 CAR studies suggest that prolonged T cell persistence at high levels is crucial for triggering long-lasting responses. CD19 CARs that reduce T cell exhaustion may lead to improved clinical responses. Therefore, in the treatment of autoimmune diseases, there is a need for alternative CARs to CD19 that do not involve the aforementioned disadvantages. [Prior art documents] [Non-patent literature]

[0026] [Non-Patent Document 1] Tsokos GC. (2011). Systemic lupus erythematosus. N Engl J Med 365(22):2110-21 [Non-Patent Document 2] Kaul A, Gordon C, Crow M, et al. (2016). Systemic lupus erythematosus. Nature Reviews 2:1-21 [Non-Patent Document 3] Mackensen A, Muller F, Mouglakakos D, et al. (2022). Anti-CD19 CAR T cell therapy for refractory lupus erythematosus. Nature Medicine 28:2124-2132 [Non-Patent Document 4] Merrill J, Neuwelt CM, Wallace DJ, Shanahan JC, et al. (2010). Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II / III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222-33 [Non-Patent Document 5] Rovin et al., (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum 64(4): 1215-26 [Non-Patent Document 6] Rovin et al., Lancet 2021(www.doi.org / 10.1016 / S0140-6736(21)00578-X) [Non-Patent Document 7] Cappell KM, Kochenderfer JN. (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Review 20:359-371 [Non-Patent Document 8] Westin J, Davis RE, Feng L, Hagemeister F, et al. (2023). Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol 41(4):745–55

Outdoor Tools9

Outdoor Tools 10

Outdoor Content11

Outdoor Tools 12

Non-licensed Document 13

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

[0027] overview This disclosure provides a method for treating autoimmune diseases with CD19 CAR T cells. Treatment with CD19 CAR T cells is intended to more effectively eliminate autoreactive B cells by targeting the B cell compartment more completely than rituximab. CD19 is more broadly expressed in B cells, including very early B progenitor cells and immature plasmablasts, making it advantageous as a target in autoimmune diseases compared to CD20-targeted therapy.

[0028] Therefore, in the first aspect, the present invention provides a method for treating an autoimmune disease in a patient, in which the patient, a) The following array: CDR1 - GYAFSSS(Sequence ID 1); CDR2 - YPGDED (Sequence ID 2) CDR3 - SLLYGDYLDY (Sequence ID 3) Heavy chain variable region (VH) having a complementarity determination region (CDR); and b) The following array: CDR1 - SASSSVSYMH(Sequence ID 4); CDR2 - DTSKLAS (Sequence ID 5) CDR3 - QQWNINPLT (Sequence ID 6) Light chain variable region (VL) having a CDR having The patient is administered cells containing a chimeric antigen receptor (CAR) that includes a CD19-binding domain.

[0029] The autoimmune disease may be systemic lupus erythematosus (SLE). The autoimmune disease may be severe SLE or refractory SLE.

[0030] The cells can be T cells or NK cells. The cells can be autologous peripheral blood T cells transduced ex vivo to express CAR. The cells may be isolated from a patient-derived peripheral blood mononuclear cell (PBMC) sample.

[0031] 50×10 6 A dose of (±20%) CD19 CAR-positive viable T cells can be administered to the patient. Alternatively, the dose can be 100×10 6 (±20%) CD19 CAR-positive viable T cells or 30×10 6 (±20%) CD19 CAR-positive viable T cells.

[0032] The administration can be intravenous injection through a Hickman line or a peripherally inserted central venous catheter.

[0033] The CD19 binding domain can comprise 6 CDRs (SEQ ID NOs: 1 to 6) grafted onto a human antibody framework.

[0034] The CD19 binding domain can comprise a VH domain having the sequence set forth as SEQ ID NO:7 and / or a VL domain having the sequence set forth as SEQ ID NO:8, or a variant of either having at least 95% sequence identity.

[0035] The CD19 binding domain can comprise an scFv in a VH-VL orientation.

[0036] The CD19 binding domain can comprise the sequence set forth as SEQ ID NO:9, or a variant thereof having at least 90% sequence identity.

[0037] The CAR can comprise a spacer that is a CD8 stalk.

[0038] The CAR can comprise an intracellular T cell signaling domain comprising a 4-1BB endodomain and a CD3-zeta endodomain.

[0039] In a second aspect, the present invention provides a method for treating an autoimmune disease in a patient, the method being 50 × 10 6 The procedure includes administering a dose of (±20%) CD19 CAR-positive viable T cells to the patient. Alternatively, the patient may administer 30 × 10 6 A dose of (±20%) CD19 CAR-positive viable T cells may be administered. Alternatively, the patient may receive 100 × 10⁶ 6 A dose of (±20%) CD19 CAR-positive viable T cells may be administered.

[0040] The autoimmune disease in the second aspect may be SLE. The autoimmune disease may be severe SLE or refractory SLE.

[0041] In the first or second embodiment, the CAR may include a sequence shown as any of SEQ ID NOs: 10-15, or a variant thereof having at least 80% sequence identity but retaining i) the ability to bind to CD19 and ii) the ability to induce T cell signaling. The CAR may have advantageous properties compared to fmc63-based CARs used in UPENN studies. For example, the CD19(CAT)CAR herein has a lower affinity CD19 conjugate with a faster dissociation rate that more faithfully reflects physiological interactions and therefore more physiological T cell activation. This is intended herein to reduce the toxicity of cells expressing its CAR, reduce the T cell exhaustion tendency of such cells, and, consequently, improve the ability of programmed T cells to enhance persistence and participate in the continuous killing of target cancer cells. As another example, when a CAR is expressed by T cells and used to target CD19-expressing cells, it may induce lower IFNγ release by CD19-expressing target cells than that caused by T cells expressing a CAR containing a CD19-binding domain, which includes a) a heavy chain variable region (VH) with a complementarity-determining region (CDR) having the following sequences: CDR1 - GVSLPDY (SEQ ID NO: 16); CDR2 - WGSET (SEQ ID NO: 17); CDR3 - HYYYGGSYAMDY (SEQ ID NO: 18); and b) a light chain variable region (VL) with a CDR having the following sequences: CDR1 - RASQDISKYLN (SEQ ID NO: 19); CDR2 - HTSRLHS (SEQ ID NO: 20); CDR3 - QQGNTLPYT (SEQ ID NO: 21). The CDRs provided herein may be grafted onto a human framework or a humanized framework. [Brief explanation of the drawing]

[0042] [Figure 1] SLEDAI-2K score of the first SLE patient treated with obe-cel. [Figure 2] CAR-T cell expansion in the first SLE patient treated with obe-cel. A) Flow cytometry of CD3+CAT19+ cells. B) ddPCR. [Modes for carrying out the invention]

[0043] Detailed explanation Chimeric antigen receptor (CAR) Chimeric antigen receptors (CARs), also known as chimeric T cell receptors, artificial T cell receptors, and chimeric immune receptors, are engineered receptors that graft arbitrary specificity onto immune effector cells. In classical CARs, the specificity of a monoclonal antibody is grafted onto the T cell. The nucleic acid encoding the CAR can be transferred into the T cell, for example, using a retroviral vector. In this way, a large number of CD19-specific T cells can be generated for adoptive cell transfer. Phase I clinical studies of this approach have demonstrated efficacy.

[0044] The target antigen-binding domain of a CAR is typically fused to the endodomain via a spacer and transmembrane domain. The endodomain may contain, or can associate with, an intracellular T cell signaling domain. When a CAR binds to a target antigen, this results in the transmission of an activation signal to T cells expressing the CAR on their surface.

[0045] CD19 target antigen-specific binding domain The human CD19 antigen is a 95 kD transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, possessing a single transmembrane domain, a cytoplasmic C-terminus, and an extracellular N-terminus. CD19 is expressed very early in B cell differentiation and disappears only at the final stage of B cell differentiation into plasma cells. CD19 is a biomarker for normal B cells and follicular dendritic cells. CD19 primarily acts as a B cell co-receptor, along with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, leading to binding by Src family kinases and recruitment of PI-3 kinase.

[0046] CD19 is also expressed in all B-cell malignancies but not in multiple myeloma cells. It is not expressed in other hematopoietic populations or non-hematopoietic cells, and therefore, targeting this antigen should not cause toxicity in the bone marrow or non-hematopoietic organs. The loss of normal B-cell compartments is considered an acceptable toxicity when treating lymphoid malignancies because effective CD19 CAR T-cell therapy will result in B-cell aplasia, but the resulting hypogammaglobulinemia can be treated with pooled immunoglobulins.

[0047] Different designs of CARs have been tested against CD19 in various clinical trials, as outlined in Table 2 below. [Table 2]

[0048] As shown above, most of the studies conducted to date have used scFv derived from the hybridoma fmc63 as part of the CD19-recognizing binding domain.

[0049] The antigen-binding domain of a CD19-binding CAR (hereinafter referred to as a CD19 CAR) may be any domain capable of binding to CD19.

[0050] For example, the antigen-binding domain may include the CD19 antigen-binding domains listed in Table 3. [Table 3]

[0051] The gene encoding CD19 contains 10 exons, with exons 1-4 encoding the extracellular domain, exon 5 encoding the transmembrane domain, and exons 6-10 encoding the cytoplasmic domain. The antigen-binding domain of the CD19 CAR described herein may bind to the CD19 epitope encoded by exon 1 of the CD19 gene. The antigen-binding domain of the CD19 CAR described herein may bind to the CD19 epitope encoded by exon 2 of the CD19 gene. The antigen-binding domain of the CD19 CAR described herein may bind to the CD19 epitope encoded by exon 3 of the CD19 gene. The antigen-binding domain of the CD19 CAR described herein may bind to the CD19 epitope encoded by exon 4 of the CD19 gene.

[0052] The CD19 binding domain illustrated herein is a) Heavy chain variable region (VH) having a CAT19 CDR having the following sequence: CDR1 - GYAFSSS (Sequence ID 1), CDR2 - YPGDED (Sequence ID 2) and CDR3 - SLLYGDYLDY (Sequence ID 3), and b) Light chain variable region (VL) having a CAT19 CDR with the following sequence: CDR1 - SASSSVSYMH (Sequence ID 4), CDR2 - DTSKLAS (SEQ ID NO: 5) and CDR3 - QQWNINPLT (Sequence ID 6) It includes a variable region having an antibody-derived complementarity-determining region (CDR) called CAT19. The CAT19 antibody is described in WO2016 / 139487.

[0053] The aim is to introduce one or more mutations (substitutions, additions, or deletions) into one or more CDRs without negatively affecting CD19 binding activity. Each CDR may have, for example, one, two, or three amino acid mutations. The CDR may also be in the form of a single-stranded variable fragment (scFv), which is a fusion protein in which the heavy chain variable region (VH) and light chain variable region (VL) of an antibody are linked by a short linker peptide of 10 to about 25 amino acids. The scFv may be VH-VL oriented, i.e., VH is at the amino terminus of the CAR molecule, and the VL domain is linked to a spacer, which is then linked to the transmembrane and endo domains.

[0054] The CDR may be grafted onto a human antibody or scFv framework. For example, the CAR may consist of one of the following sequences or include a CD19-binding domain containing one of them.

[0055] CD19 CAR may contain the following VH sequence: VH sequence derived from the SEQ ID NO: 7-CAT19 mouse monoclonal antibody [ka]

[0056] CD19 CAR may contain the following VL sequences. VL sequence derived from the SEQ ID NO: 8-CAT19 mouse monoclonal antibody [ka]

[0057] CD19 CAR may contain the following scFv sequences. SEQ ID NO: 9 - VH-VL scFv sequence derived from mouse monoclonal antibody [ka]

[0058] A CAR may consist of or contain one of the following sequences: Sequence ID 10 - CAT19 CAR using the "Campana" architecture [ka] The "Campana" architecture refers to a CAR having a CD8a spacer and transmembrane domain, a 4-1BB end domain, and a TCR CD3z end domain.

[0059] Sequence ID 11-OX40- CAT19 CAR having a zeta-endodomain [ka]

[0060] CAT19 CAR with sequence number 12-CD28-zetaendodomain [ka]

[0061] Sequence ID 13 - Third generation CD19 CAR [ka]

[0062] CD19 CAR with Sequence ID No. 14-IgG1 hinge spacer [ka] [ka]

[0063] Sequence ID 15 - A CD19 CAR with a hinge-CH2-CH3 structure similar to human IgG1 and a mutated FcR binding site. [ka]

[0064] The CARs provided herein may include variants of the polypeptides of SEQ ID NOs. 1-15 having at least 80, 85, 90, 95, 98, or 99% sequence identity, provided that the variant sequence retains the ability to bind to CD19 (when combined with a complementary VL domain or VH domain, where appropriate). The percentage of identity between two polypeptide sequences can be readily determined by a program such as BLAST, which is freely available at blast.ncbi.nlm.nih.gov.

[0065] The CD19 CAR illustrated herein (i.e., CAT19CAR using the "Campana" architecture, SEQ ID NO: 10) possesses the properties intended by this disclosure, resulting in low toxicity and good efficacy in treated patients. Compared with fmc63-CampanaCAR, the CAT19CAR illustrated herein achieved killing of CD19-expressing target cells and proliferated in response to CD19-expressing targets, but with less interferon-gamma release. Furthermore, in a small animal model of progressive B-cell lymphoma, fmc63-based CAR-T cells and CAT19-based CAR-T cells showed comparable efficacy and engraftment, but surprisingly, fewer exhausted CAT19 CAR T cells were observed than fmc63 CAR T cells. See Examples 2 and 3 of U.S. Publication No. 2018-0044417.

[0066] The CAT19CAR provided herein may induce 25, 50, 70, or 90% lower IFNγ release in comparative assays involving contact between CAR T cells and target cells. The CAT19CAR provided herein may result in a lower proportion of CAR T cells becoming exhausted compared to fmc63 CAR T cells. T cell exhaustion can be assessed using methods known in the art, e.g., analysis of PD-1 expression. The CAR may result in 20, 30, 40, 50, 60, or 70% fewer CAR T cells expressing PD-1 compared to fmc63 CAR T cells in comparative assays involving contact between CAR T cells and target cells.

[0067] Another exemplary CD19 antigen-binding domain contemplated by this disclosure is based on the CD19 antigen-binding domain CD19ALAb (described in WO2016 / 102965), which is, a) Heavy chain variable region (VH) having a CDR having the following sequence: CDR1 - SYWMN(SEQ ID NO: 44); CDR2 - QIWPGDGDTNYNGKFK (Sequence ID 45) CDR3 - RETTTVGRYYYAMDY(Sequence ID 46); and b) Light chain variable region (VL) having a CDR having the following sequence: CDR1 - KASQSVDYDGDSYLN(Sequence ID 47); CDR2 - DASNLVS (Sequence ID 48) CDR3 - QQSTEDPWT (Sequence ID 49) Includes.

[0068] The aim is to enable the introduction of one or more mutations (substitutions, additions, or deletions) into one or more CDRs without negatively affecting CD19 binding activity. Each CDR may, for example, have one, two, or three amino acid mutations.

[0069] CAR may contain one of the following amino acid sequences: Sequence ID 22 - Mouse CD19ALAb scFv sequence [ka] [ka]

[0070] Sequence ID 23 - Humanized CD19ALAb scFv sequence - Heavy chain 19, Kappa 16 [ka]

[0071] Sequence ID 24 (Humanized CD19ALAb scFv sequence - heavy chain 19, kappa 7) [ka]

[0072] scFv may be in a VH-VL orientation (as shown in SEQ ID NOs. 9, 22, 23, and 24) or in a VL-VH orientation.

[0073] CAR may contain one of the following VH sequences: Sequence ID 25 - Mouse CD19ALAb VH sequence [ka]

[0074] Sequence ID 26 - Humanized CD19ALAb VH sequence [ka]

[0075] CAR may contain one of the following VL sequences. Sequence ID 27 - Mouse CD19ALAb VL sequence [ka] Sequence ID 28 (Humanized CD19ALAb VL sequence, Kappa-16) [ka] Sequence ID 29 - Humanized CD19ALAb VL sequence, Kappa7 [ka]

[0076] The CARs provided herein may include variants of the sequences represented as any of SEQ ID NOs: 16-29 having at least 80, 85, 90, 95, 98, or 99% sequence identity, provided that the variant sequences retain the ability to bind to CD19 (when combined with a complementary VL domain or complementary VH domain, where appropriate). The CARs provided herein may include variants of the sequences represented as any of SEQ ID NOs: 22-29 or 44-49 having at least 80, 85, 90, 95, 98, or 99% sequence identity, provided that the variant sequences retain the ability to bind to CD19 (when combined with a complementary VL domain or complementary VH domain, where appropriate). The percentage of identity between two polypeptide sequences can be easily determined by programs such as BLAST, which is freely available at blast.ncbi.nlm.nih.gov.

[0077] transmembrane domain A transmembrane domain is a CAR domain that spans the membrane.

[0078] A transmembrane domain can be any protein structure that is thermodynamically stable in a membrane. Typically, this is an alpha-helix composed of multiple hydrophobic residues. A transmembrane domain of any transmembrane protein can be used to provide the transmembrane portions provided herein. The presence and segment of a protein's transmembrane domain can be determined by those skilled in the art using the TMHMM algorithm (http: / / www.cbs.dtu.dk / services / TMHMM-2.0 / ). Furthermore, given that a protein's transmembrane domain is a relatively simple structure—a polypeptide expected to form a hydrophobic alpha-helix of sufficient length to span the membrane—artificially designed transmembrane domains can also be used (U.S. Patent No. 7052906B1 describes synthetic transmembrane components).

[0079] The transmembrane domain may be derived from CD28, which contributes to excellent receptor stability. The CD28 transmembrane domain is shown as Sequence ID No. 50. Sequence ID 50 FWVLVVVGGVLACYSLLVTVAFIIFWV

[0080] The transmembrane domain may be derived from human Tyrp-1. The tyrp-1 transmembrane domain sequence is shown as sequence number 51. Sequence ID 51 IIAIAVVGALLLVALIFGTASYLI

[0081] The transmembrane domain may originate from CD8A. The CD8A transmembrane domain sequence is shown as sequence number 52. Sequence ID 52 IYIWAPLAGTCGVLLLSLVITLYC

[0082] Intracellular T cell signaling domain (endodomain) The endodomain is the signaling portion of CARs. After antigen recognition, receptors cluster together and transmit signals to cells. The most commonly used endodomain component is that of CD3-zeta containing three ITAMs. This transmits an activation signal to T cells after antigen binding. CD3-zeta may not always provide a sufficiently qualified activation signal, and additional co-stimulatory signaling may be required. For example, an endodomain derived from CD28, OX40, or 41BB can be used with CD3-zeta to transmit proliferation / survival signals, or all three can be used together.

[0083] Early CAR designs had endodomains derived from either the γ chain of FcεR1 or the intracellular portion of CD3ζ. As a result, such first-generation receptors transmitted immunological signal 1, which was sufficient to trigger T cell death of cognitive target cells, but could not fully activate T cells to proliferate and survive. To overcome this limitation, composite endodomains were constructed. Fusion of the intracellular portion of a T cell costimulatory molecule to the intracellular portion of CD3ζ resulted in second-generation receptors capable of simultaneously transmitting activation and costimulatory signals after antigen recognition. The most commonly used costimulatory domain was that of CD28, which delivers the most potent costimulatory signal, i.e., immunological signal 2, triggering T cell proliferation. Several receptors containing TNF receptor family endodomains, such as OX40 and 41BB, that transmit survival signals have also been described. Finally, even more potent third-generation CARs with endodomains capable of transmitting activation, proliferation, and survival signals have been described.

[0084] The CAR end domain of the present invention may include one or more combinations of the CD3-zeta end domain, 41BB end domain, OX40 end domain, or CD28 end domain.

[0085] The intracellular T cell signaling domain (endodomain) of the CAR of the present invention may include the sequence shown as SEQ ID NOs. 53, 54, 55, 56, 57, 30, 31, or 32, or a variant thereof having at least 80% sequence identity. Sequence ID 53 (CD3 zeta-end domain) [ka] Sequence ID 54 (41BB end domain) [ka] Sequence ID 55 (OX40 end domain) [ka] Sequence ID 56 (CD28 end domain) [ka]

[0086] Examples of such end-domain combinations include 41BB-Z, OX40-Z, CD28-Z, and CD28-OX40-zeta. Sequence ID 57 (41BB-Z end-domain fusion) [ka] Sequence ID 30 (OX40-Z end-domain fusion) [ka] Sequence ID 31 (CD28Z end-domain fusion) [ka] Sequence ID 32 (CD28OXZ) [ka]

[0087] The variant sequence may have at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NOs. 25, 26, 27, 28, 29, 30, 31, or 32, provided that the sequence provides a valid transmembrane domain / intracellular T cell signaling domain.

[0088] Signal peptide The CAR of the present invention may contain a signal peptide, and when the CAR is expressed inside a cell such as a T cell, the newly synthesized protein is directed toward the endoplasmic reticulum, and then toward the cell surface, where the newly synthesized protein is expressed.

[0089] The core of a signal peptide can contain a long sequence of hydrophobic amino acids that tend to form a single alpha-helix. A signal peptide can begin with a short sequence of positively charged amino acids that help enforce the correct topology of the polypeptide during transition. The terminus of a signal peptide typically contains a sequence of amino acids that are recognized and cleaved by a signal peptidase. The signal peptidase can cleave the signal peptide either during or after transition to produce a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease.

[0090] Signal peptides can be located at the amino terminus of a molecule.

[0091] The CAR of the present invention may have the following general formula: Signal peptide - CD19 binding domain - Spacer domain - Transmembrane domain / Intracellular T cell signaling domain.

[0092] The signal peptide may contain variants with 5, 4, 3, 2, or 1 amino acid mutations (insertions, substitutions, or additions), provided that the signal peptide still functions to induce cell surface expression of the CAR.

[0093] The signal peptide of SEQ ID NO: 33 is small and highly efficient. It is predicted to undergo approximately 95% cleavage after the terminal glycine, which will result in efficient removal by the signal peptidase. Sequence ID 33: METDTLLLWVLLLWVPGSTG

[0094] The signal peptide of SEQ ID NO: 34 is small and highly efficient. It is predicted to undergo approximately 95% cleavage after the terminal glycine, which will result in efficient removal by the signal peptidase. Sequence ID 34 MGTSLLCWMALCLLGADHADA

[0095] The signal peptide of SEQ ID NO: 35 is derived from IgG1. Sequence ID 35: MSLPVTALLLPLALLLHAARP

[0096] The signal peptide of SEQ ID NO: 36 is derived from CD8. Sequence ID 36: MAVPTQVLGLLLLWLTDARC

[0097] Spacer The CAR of the present invention may include a spacer sequence that connects the CD19-binding domain to the transmembrane domain and spatially separates the CD19-binding domain from the endodomain. The movable spacer allows the CD19-binding domain to be oriented in different directions to enable CD19 binding.

[0098] The spacer sequence may include, for example, an IgG1 Fc region, an IgG1 hinge, or a CD8 stalk, or a combination thereof. Alternatively, the spacer may include an alternative sequence having similar length and / or domain spacing characteristics to the IgG1 Fc region, IgG1 hinge, or CD8 stalk.

[0099] The human IgG1 spacer may be modified to remove the Fc-binding motif.

[0100] Examples of amino acid sequences for these spacers are shown below: Sequence ID 37 (Human IgG1 hinge-CH2CH3) [ka] Sequence ID 38 (Human CD8 Stork): [ka] Sequence ID 39 (Human IgG1 Hinge): [ka] Sequence ID 40 (IgG1 Hinge-Fc) [ka] Sequence ID 41 (Fc modified to remove the IgG1 hinge-Fc receptor recognition motif) [ka] Modified residues are indicated by an underline; * indicates a deletion. Sequence ID 42 (CD2 ectodomain) [ka] Sequence ID 43 (CD34 ectodomain) [ka]

[0101] Interferon release and CAR T cell exhaustion The inventors have found that CD19 CAR based on CAT19 scFv possesses properties that can result in lower toxicity and better efficacy.

[0102] Considering that the primary experience with CD19 CAR therapy is with fmc63 scFv-based CARs, and that the oldest, largest, and perhaps most significant clinical dataset is with fmc63-based Campana CARs, we have designated this Campana CAR as the "gold standard." Therefore, we compared fmc63-Campana CARs with similar CARs that have CAT19 scFv instead of fmc63. Surprisingly, we found that CAT19 CAR T cells proliferated in response to CD19-expressing targets, causing the death of CD19-expressing target cells, while exhibiting less interferon-gamma release. Furthermore, small animal models of high-grade B-cell lymphoma showed comparable efficacy and engraftment between fmc63-based CARs and CAT19-based CARs, but surprisingly, fewer CAT19 CAR T cells were exhausted than fmc63 CAR T cells.

[0103] The CAR of the present invention can induce 25, 50, 70, or 90% lower IFNγ release in a comparative assay involving contact between CAR T cells and target cells.

[0104] The CAR of the present invention can cause a smaller proportion of CAR T cells to become exhausted compared to fmc63 CAR T cells. T cell exhaustion can be evaluated using methods known in the art, such as analysis of PD-1 expression. In a comparative assay involving contacting CAR T cells with target cells, the CAR of the present invention can cause PD-1 to be expressed in 20, 30, 40, 50, 60, or 70% fewer CAR T cells than in fmc63 CAR T cells.

[0105] nucleic acid sequence A second aspect of the present invention relates to nucleic acid sequences encoding the CAR of the method described herein.

[0106] The nucleic acid sequence may be capable of encoding a CAR having the amino acid sequence shown as one of sequence numbers 10-15.

[0107] As used herein, the terms “polynucleotide,” “nucleotide,” and “nucleic acid” are intended to be synonymous with each other.

[0108] Nucleic acids can be, for example, RNA, DNA, or cDNA. Nucleic acids may include DNA or RNA. These may be single-stranded or double-stranded. They may also be polynucleotides containing synthetic or modified nucleotides.

[0109] Several different types of modifications to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, and the addition of acridine or polylysine chains at the 3' and / or 5' ends of the molecule. It should be understood that for the purposes of use described herein, polynucleotides may be modified by any method available in the art. Such modifications may be made to enhance the in vivo activity or lifetime of the target polynucleotide.

[0110] Alternative codons may be used in regions of sequences encoding the same or similar amino acid sequences to avoid homologous recombination when both CARs are encoded by the same vector.

[0111] Due to the degeneracy of the gene code, it is possible to use alternative codons that encode the same amino acid sequence. For example, both the codons "ccg" and "cca" encode the amino acid proline, and therefore "cca" can be used instead of "ccg" without affecting the amino acid at that position in the sequence of the translated protein.

[0112] Alternative RNA codons that can be used to encode each amino acid are summarized in Table 4. [Table 4]

[0113] Alternative codons may be used in the portion of the nucleic acid encoding the spacer in the first CAR and the portion of the nucleic acid encoding the spacer in the second CAR, particularly when the same or similar spacers are used in the first CAR and the second CAR.

[0114] Alternative codons may be used in the nucleic acid portion encoding the transmembrane domain of the first CAR and the nucleic acid portion encoding the transmembrane domain of the second CAR, particularly when the same or similar transmembrane domains are used in the first and second CARs.

[0115] Alternative codons may be used in one or more nucleic acids that encode a co-stimulatory domain, such as the CD28 endodomain.

[0116] Alternative codons can be used in one or more domains that transmit survival signals, such as the OX40 and 41BB end domains.

[0117] Alternative codons can be used in the nucleic acid portion encoding the CD3 zeta-end domain, and / or the nucleic acid portion encoding one or more costimulatory domains, and / or the nucleic acid portion encoding one or more domains that transmit survival signals.

[0118] vector The present invention also provides a vector comprising a nucleic acid sequence according to the present invention. Such a vector can be used to introduce the nucleic acid sequence into a host cell such that the nucleic acid sequence expresses and produces a molecule according to a first aspect of the present invention.

[0119] The vector may be, for example, a plasmid or viral vector, such as a retroviral vector or a lentiviral vector.

[0120] Vectors may be capable of transfecting or transducing cells such as T cells.

[0121] cell The present invention also provides cells containing nucleic acids according to the present invention. The present invention provides cells expressing CARs provided herein on the cell surface.

[0122] The cells could be any eukaryotic cell capable of expressing CARs on its cell surface, such as immunological cells.

[0123] Specifically, the cells may be immune effector cells, such as T cells or natural killer (NK) cells.

[0124] T cells, or T lymphocytes, are a type of lymphocyte that plays a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of T cell receptors (TCRs) on their cell surface. Various types of T cells exist, as outlined below.

[0125] Helper T cells (TH cells) assist other leukocytes in immunological processes, including the maturation of B cells into plasma cells and memory B cells, as well as the activation of cytotoxic T cells and macrophages. TH cells express CD4 on their surface. TH cells are activated when peptide antigens are presented to them by MHC class II molecules on the surface of antigen-presenting cells (APCs). These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines that promote different types of immune responses.

[0126] Cytotoxic T cells (TC cells or CTLs) destroy virus-infected cells and tumor cells, and are also involved in graft rejection. CTLs express CD8 on their surface. These cells recognize their targets by binding to antigens associated with MHC class I, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, CD8+ cells can be inactivated and enter an anerious state, thereby preventing autoimmune diseases such as experimental autoimmune encephalomyelitis.

[0127] Memory T cells are a subset of antigen-specific T cells that persist for a long period after an infection has subsided. Upon re-exposure to the same antigen, they rapidly expand into numerous effector T cells, thus providing the immune system with a "memory" of past infection. Memory T cells include three subtypes: central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells can be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO.

[0128] Regulatory T cells (Treg cells), formerly known as suppressor T cells, are crucial for maintaining immune tolerance. Their primary roles are to halt T cell-mediated immunity towards the end of the immune response and to suppress autoreactive T cells that have escaped the negative selection process in the thymus. Two major classes of CD4+ Treg cells are described: naturally occurring Treg cells and adoptive Treg cells.

[0129] Naturally occurring Treg cells (also known as CD4+CD25+FoxP3+Treg cells) are associated with interactions between T cells that originate and develop in the thymus and both myeloid dendritic cells (CD11c+) and plasmacytoid dendritic cells (CD123+) activated by TSLP. Naturally occurring Treg cells can be distinguished from other T cells by the presence of an intracellular molecule called FoxP3. Mutations in the FOXP3 gene can prevent the development of regulatory T cells and can lead to the lethal autoimmune disease IPEX.

[0130] Adoptive Treg cells (also known as Tr1 cells or Th3 cells) can arise during a normal immune response.

[0131] The T cells provided herein may be any of the T cell types described above, in particular, CTLs.

[0132] Natural killer (NK) cells are a type of cytolytic cell that forms part of the innate immune system. NK cells provide a rapid response to innate signals from virus-infected cells in a manner that is independent of MHC.

[0133] NK cells (belonging to the group of innate lymphoid cells) are defined as large granular lymphocytes (LGLs) and constitute a third type of cell that differentiates from common lymphoid progenitor cells that give rise to B lymphocytes and T lymphocytes. NK cells are known to differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus before entering circulation.

[0134] The cells expressing the CARs provided herein may be any of the cell types described above.

[0135] The CAR-expressing cells of the present invention can be generated ex vivo. The cells may be derived from cell samples such as peripheral blood mononuclear cell (PBMC) samples from a patient or donor. The cells may be activated and / or enlarged before transduction with CAR-coding nucleic acids, for example, by treatment with an anti-CD3 monoclonal antibody.

[0136] Alternatively, the T cells or NK cells provided herein may be derived from ex vivo differentiation of inducible progenitor cells or embryonic progenitor cells into T cells or NK cells.

[0137] Alternatively, immortalized T cell lines that retain their lysis function and can act as therapeutic agents may be used.

[0138] Obecabtagene autoleucel (referred to herein as "obe-cel") consists of autologous peripheral blood T cells transduced ex vivo with a lentiviral vector encoding the CD19 CAR "CD19(CAT)CAR" disclosed herein, which has lower affinity and faster detachment from CD19 compared to the CD19(FMC63)CAR used in the approved CAR T cell therapies Kymriah® (tisagenlecleucel), Yescarta® (axicabutagene silolucel), and Tecartus® (brexcabutagene autoleucel).

[0139] The binding kinetics of CAT scFv (used in obe-cel) and recombinant CD19, as well as the binding kinetics of FMC63 scFv (used in axicapbutagen silolucel and tisagenlecleucel) and recombinant CD19, were determined using surface plasmon resonance. Equilibrium dissociation constants (KD) were determined to be 14.4 nM for CAT and 0.328 nM for FMC63 when the data were fitted to a 1:1 Langmuir coupling model. A KD of less than 1 / 40th for CAT scFv indicates a much faster dissociation rate (CAT: 3.1 × 10⁻⁶). -3 s -1 vs FMC63: 6.8 × 10 -5 s -1 While the result was as follows, the on-rate binding was equivalent (CAT: 2.2 × 10⁻¹⁰). 5 M -1 s -1 vs. FMC63: 2.1 × 10 5 M -1 s -1 ).

[0140] When co-cultured with Raji cells and NALM-6 cells, CD19(CAT)CAR T cell proliferation was greater than that of CD19(FMC63)CAR T cells. This enhanced proliferation indicated an IL-2-independent mechanism, rather than being a result of increased IL-2 production.

[0141] Normal donor T cells were transduced to express CD19(CAT)CAR or CD19(FMC63)CAR, challenged with Raji cells (a CD19-expressing Burkitt lymphoma cell line), and pro-inflammatory cytokines in the supernatant were analyzed at 48 hours. The cytokine release profiles were similar in both CAR-expressing T cell lines, except that tumor necrosis factor α secretion from CD19(CAT)CAR T cells was higher than that from CD19(FMC63)CAR T cells (in that order, mean 750.7±103.3 pg / mL and 292.1±36.51 pg / mL, respectively; n=4, p<0.01).

[0142] standard 51In Cr-releasing assays, T cells transduced to express CD19(CAT)CAR or CD19(FMC63)CAR were incubated with CD19-negative targets and CD19-expressing targets. Cell death was significantly greater for CD19(CAT)CAR T cells than for CD19(FMC63)CAR T cells, particularly at low effector-to-target ratios.

[0143] The antitumor efficacy of CD19(CAT)CAR T cells and CD19(FMC63)CAR T cells was evaluated and compared in a NALM-6 NSG-mouse xenograft model. Rapid disseminated tumor infiltration was observed in control mice receiving untransduced T cells. CD19(FMC63)CAR T cells slowed tumor growth but did not prevent it. In contrast, an equivalent number of CD19(CAT)CAR T cells resulted in tumor regression. A substantial difference in tumor volume was observed 12 days after T cell injection; mean CD19(CAT)CAR T cells: 1.1 × 10⁶ 8 ~9.3×10 7 photons / second / cm 2 / Steradian; CD19(FMC63)CAR T cell 3.2×10 9 ~7.7×10 8 photons / second / cm 2 / steradian, n=18, p<0.001. Blood and bone marrow (BM) were analyzed for residual tumor cells and persistent CAR T cells two weeks after injecting CAR T cells into NALM-6 NSG mice. A significantly higher number of residual NALM-6 tumor cells were observed in the BM of the CD19(FMC63)CAR T cell cohort compared to the CD19(CAT)CAR T cell cohort (mean 2.8 × 10⁶). 5 vs 3 x 10 2 (10⁴ NALM-6 cells / mL, p<0.0001). Conversely, a significantly larger absolute number of CD19(CAT)CAR T cells than CD19(FMC63)CAR T cells was observed in BM of NALM-6 NSG mice (mean 3.4 × 10⁴). 4 CD19(CAT)CAR T cells / mL vs 1.3 × 10 4(individual CD19(FMC63)CAR T cells / mL, n=18, p<0.05), and also in peripheral blood (mean: 1.9 × 10⁶). 4 CD19(CAT)CAR T cells / mL vs 2.8 × 10⁶ 3 The number of CD19(FMC63)CAR T cells / mL (n=9, p<0.001) persisted.

[0144] In summary, the CAT scFv binding domain used in obe-cel has less than 1 / 40th the affinity for recombinant CD19 in vitro compared to the FMC63 scFv binding domain used in other CAR T products. CD19(CAT)CAR allows transduced T cells to proliferate, secrete cytokines in response to CD19-positive targets, and specifically lyse CD19-positive cell lines in vitro with greater cytotoxicity compared to CD19(FMC63)CAR T cells. CD19(CAT)CAR T cells also exhibit superior antitumor efficacy and engraftment compared to CD19(FMC63)CAR T cells in the NSG NALM-6 mouse model of leukemia.

[0145] Clinical experience with obe-cel CAR T cells includes clinical studies in various hematological malignancies. Currently, there are four ongoing studies evaluating obe-cel in pediatric and adult patients with B-cell acute lymphoblastic leukemia (B ALL) and other B-cell malignancies: three investigator-initiated Phase I studies, CARPALL (EudraCT 2015-001144-10 2019, NCT02443831 2016) (Ghorashian S, Kramer AM, Onuoha S, Wright G, et al. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 25(9):1408-14), ALLCAR19 (EudraCT 2016-004027-22, NCT02935257 2017) (Roddie C, Dias J, O'Reiilly MA, et al. (2021). Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol; 39(30):3352-63; Roddie C, Dias J, O'Reilly M, Mitsikakou M, et al. (2022a). Safety, efficacy and long-term follow-up of AUTO1, a fost-off rate CD19 CAR in relapsed / refractory B-cell acute lymphoblastic leukaemia and other B-cell malignancies.American Society of Hematology Annual Meeting Poster 3318; Roddie C, Dias J, O'Reilly M, Mitsikakou M, et al. (2023b). Long-term follow-up of AUTO1, a fast-off rate CD19 CAR, in relapsed / refractory B-cell acute lymphoblastic leukemia and factors associated with durable response. American Society for Transplantation and Cellular Therapy Annual Meeting Poster 277), CAROUSEL (NCT04443829) (Roddie C, Dias J, O'Reilly M, Green L. (2022c). Safety and efficacy findings of AUTO1, a fast-off rate CD19 CAR, in relapsed / refractory primary CNS lymphoma. European Hematology Association Annual Meeting Poster P1460), and one Phase Ib / II study sponsored by Autolus in adult patients with relapsed / refractory B-ALL. The AUTO1-AL1 (FELIX) study (EudraCT 2019-001937-16, NCT04404660). The Phase II portion of the FELIX study is the central study to achieve marketing approval for obe-cel (Roddie C, Sandhu KS, Tholouli E, Shaughnessy P, et al. (2023a)).Safety and effiacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed / refractory adult B-cell acute lymphoblastic leukemia (r / r B-ALL): top line result of the pivotal FELIX study. (American Society of Clinical Oncology Annual Meeting Oral abstract #7000). In total, as of August 1, 2023, 201 patients across various B-cell malignancies had been treated with obe-cel in these four studies. Based on the novel mechanism of action of the CAT CAR construct, which exhibits more physiological T cell activation and reduced cytokine release, obe-cel has a favorable safety and tolerability profile and has been shown to have very low rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) across different indications in both pediatric and adult patients (Ghorashian et al, see above; Roddie et al (2021), see above; Roddie et al (2022a), see above; Roddie et al (2023a), see above). Clinical studies using obe-cel have not been conducted in patients with autoimmune diseases. [Table 5-1] [Table 5-2] [Table 5-3]

[0146] Available clinical data on obe-cel in the treatment of patients with B ALL, derived from the Phase I studies CARPALL and ALLCAR19 and the Phase Ib / II FELIX study, support the nonclinical data and demonstrate promising efficacy with manageable toxicity in patients with r / r B ALL. • Of the 13 pediatric or young adult patients treated with obe-cel manufactured using the open process at CARPALL (Cohort 1), 10 achieved MRD-negative complete response (CR), resulting in an ORR of 77% after obe-cel infusion. All 7 patients treated with obe-cel manufactured using the closed process (Cohort 2) achieved MRD-negative CR after obe-cel infusion (ORR=100%). • Of the 20 evaluable adult patients in the ALLCAR19 study, 17 achieved MRD-negative complete response (CR), resulting in an 85% ORR after obe-cel injection. As of March 16, 2023, of 94 patients who had ≥5% blasts in their bone marrow (BM) at the time of screening and received obe-cel infusion with FELIX, 71 patients achieved CR+CRi, resulting in an ORR of 75.5%. • CRS of any grade occurred in 95% of pediatric and young adult B ALL patients in the CARPALL study, 55% of adult B ALL patients in the ALLCAR19 study, and 69% of all infused adult patients with B ALL (N=126) in the FELIX study. Three patients (2.4%) experienced a Grade 3 or higher CRS. Severe neurotoxicity was limited to one patient (5%) in the CARPALL study; three patients (15%) in the ALLCAR19 study; and nine patients (7.1%) in the FELIX study, who reported a Grade 3 or higher neurological AE / ICANS.

[0147] Preliminary results obtained in slowly progressive B NHL appear promising, with all 10 patients treated with obe-cel achieving complete molecular response (data cutoff November 18, 2021). The safety profile remains favorable in this small sample size, including 4 patients with grade 1 and 2 patients with grade 2 CRS. No ICANS of any grade were reported.

[0148] Pharmaceutical composition The present invention also relates to a pharmaceutical composition containing the CAR-expressing cells or a plurality of cells of the present invention together with a pharmaceutically acceptable carrier, diluent or excipient and optionally one or more further pharmaceutically active polypeptides and / or compounds. Such a formulation may be in a form suitable for, for example, intravenous infusion.

[0149] Treatment method Cells expressing the CAR molecules provided herein (such as T cells or NK cells) may be used to treat autoimmune diseases (in particular autoimmune diseases mediated by CD19-positive B lymphocytes or CD19-positive B cells).

[0150] This disclosure provides a method for treating a CD19-positive B lymphocyte-mediated autoimmune disease in a patient, the method comprising the step of administering CD19 CAR T cells or a population of CD19 CAR T cells to the patient.

[0151] This disclosure provides CD19 CAR T cells or populations of CD19 CAR T cells for use in the treatment of autoimmune diseases mediated by CD19-positive B lymphocytes.

[0152] This disclosure provides the use of CD19 CAR T cells or populations of CD19 CAR T cells in the manufacture of pharmaceuticals for treating autoimmune diseases mediated by CD19-positive B lymphocytes.

[0153] Examples of autoimmune diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, idiopathic inflammatory myopathy (IIM, myositis), systemic sclerosis, ANCA-associated vasculitis, inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves' disease, Hashimoto's thyroiditis or Hashimoto's disease, myasthenia gravis, neuromyelitis optica, and N-me This includes, but is not limited to, Chill-D-aspartate receptor (NMDAR) encephalitis, Lambert-Eaton syndrome, scleroderma, vasculitis, pemphigus vulgaris, pemphigus foliaceus, acquired epidermolysis bullosa, bullous pemphigoid, lupus nephritis, membranous nephropathy, Goodpasture syndrome, immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, and acquired hemophilia.

[0154] Autoimmune diseases can include SLE.

[0155] Autoimmune diseases can be a sign of severe SLE.

[0156] Autoimmune diseases can be refractory SLE.

[0157] Autoimmune diseases can be severe and refractory SLE.

[0158] SLE can present with lupus nephritis.

[0159] Lupus nephritis can be severe.

[0160] Lupus nephritis can be active.

[0161] SLE can present with active, severe lupus nephritis.

[0162] The methods for treating autoimmune diseases provided herein relate to the therapeutic use of cells or populations of cells provided herein. In this regard, the cells may be administered to subjects with a pre-existing disease or condition to reduce, lessen or improve at least one symptom associated with the disease, and / or to slow, reduce or block the progression of the disease. The methods may induce or promote cell-mediated death of CD19-expressing cells, such as B cells.

[0163] Treatment for SLE Given the crucial role of B cells in the pathogenesis of SLE disease and the evidence of the safety and activity of CD19 CAR T cell therapy, it is intended herein that infusion of a CD19 CAR T cell product (e.g., obe-cel) into a patient eliminates dysfunctional autoreactive B cells, subsequently generating normal non-autoreactive B cells.

[0164] Patients who should be treated include, but are not limited to, patients with severe, refractory SLE who, due to disease severity, one or more SLE-associated organ system lesion areas, and prior exposure to multiple SLE treatment strategies, are expected to have inadequate outcomes if treated with standard treatments.

[0165] Patients who should be treated: may have a diagnosis of SLE that meets the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus; may be positive for at least one of the following autoantibodies: 1: antinuclear antibody (ANA) with a titer of ≥80, or anti-dsDNA (≥30 IU / mL) or anti-Sm (>ULN), anti-histone or anti-chromatin (>ULN); may have severe SLE as defined below: a) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 8 points or higher (of which 4 are non-laboratory items, excluding points related to neurological findings [SLEDAI 2K items 1 to 7]) and b) at least one of the following severe SLE-related organ lesions: i) Kidney (currently moderately active, biopsy-proven lupus nephritis), ii) Moderate or severe pericarditis / myocarditis, iii) Moderate or severe pleuritis or other pulmonary lesions, iv) Vasculitis, and v) Severe hematological symptoms (e.g., severe thrombocytopenia or severe autoimmune hemolytic anemia); and / or may have refractory SLE, defined as a lack of response, insufficient response or sustained lack of response, or intolerance to: a) Hydroxychloroquine treatment in combination with corticosteroids, and b) In case of intolerance, 2 or more of the following treatment groups used for at least 3 months each or less: i) Immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid, tacrolimus, leflunomide, cyclosporine, voclosporin, or cyclophosphamide), ii) B-cell targeting agents (e.g., belimumab, anti-CD20 mAb) and iii) Cytokine inhibitors (e.g., anifrolumab).

[0166] The patient may be subjected to preconditioning chemotherapy, such as lymphodepleting chemotherapy, prior to CD19 CAR treatment. The lymphodepleting chemotherapy can include treatment with fludarabine and cyclophosphamide. The patient may receive 3 doses of 25 mg / m fludarabine on days -5, -4, and -3 relative to the CD19 CAR treatment 2 / day intravenous administration, as well as one dose of 1000 mg / m cyclophosphamide on day -3 relative to CD19 CAR treatment 2 can receive intravenous administration.

[0167] In the methods of treatment provided herein for autoimmune diseases such as SLE, the patient may receive a single dose of 50×10 6 (±20%) CD19 CAR-positive viable T cells. Contemplated alternative doses are escalating (100×10 6 [±20%] cells) or de-escalating (30×10 6 [±20%] cells) CAR-positive T cell doses. Administration can be, for example, intravenous injection through a Hickman line or a peripherally inserted central venous catheter (PICC line).

[0168] For example, it will be appreciated that there may be differences in the starting material (leukapheresate) and / or manufacture of CD19 CAR-positive T cells. These differences can result in dose variability, i.e., variability in the amount of CD19 CAR-positive T cells administered to the patient. It is contemplated herein that the dose may have a variability of ±5%, ±10%, ±15%, ±20%, ±25% or ±30%.

[0169] The treated patient will exhibit an improvement in one or more of the following assessments: Definition of SLE remission (Doris). The improvement can include SLEDAI=0 and / or PGA<0.5 on a 0 to 3 visual analog scale; Lupus low disease activity status (LLDAS). Improvement is defined as SLEDAI-2K<4 (no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever, and hemolytic anemia, or gastrointestinal activity), no new features of lupus disease activity compared to previous assessment, PGA<1 on a visual analog scale of 0-3, current prednisolone (or equivalent) dose ≤7.5 mg daily, and / or well-tolerated standard maintenance doses of immunosuppressants and approved biologics (excluding investigational drugs); Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score; Physician's General Assessment (PGA); Health Assessment Questionnaire - Disability Index (HAQ-DI); Functional assessment of chronic disease treatment - Fatigue Scale (FACIT-Fatigue) score; National assessment of estrogen safety in lupus erythematosus - SLEDAI (SELENA-SLEDAI) Relapse Index (SFI) score; Urine protein-creatinine ratio (UPCR); Autoantibody panel (antinuclear antibody [ANA], anti-double-stranded DNA [anti-dsDNA], anti-Smith, anti-RNA binding protein [anti-RBP]); Antiphospholipid antibody profiles (lupus anticoagulant, anticardiolipin antibody, and β2-glycoprotein 1); Complementary panels (CH50, C3, C4); Duration of B cell agenesis; Determination of T cell and B cell phenotypes over time by flow cytometry of peripheral blood; Determination of BlyS / BAFF concentration dynamics in peripheral blood; and Determination of cytokine concentration dynamics in peripheral blood.

[0170] Other Terminology and Disclosures Where used herein and in the appended claims, the singular forms “a,” “one,” and “the” include plural referents unless otherwise clearly indicated by context. Furthermore, it should be noted that the claims may be drafted excluding any element, for example, any element as needed. Therefore, this statement is intended to function as an antecedent for the use of exclusive terminology such as “alone,” “only,” and other “negative” limitation in relation to the description of elements of the claims.

[0171] Where a range of values ​​is provided herein, unless otherwise clearly indicated by the context, it is understood that the intermediate values ​​between the upper and lower limits of that range, up to one-tenth of the lower limit unit, as well as any other referred values ​​or intermediate values ​​within that range, are included in this disclosure. The upper and lower limits of these smaller ranges may be independently included within those smaller ranges and are also included in this disclosure, subject to any specific exclusion limits within that range. If a referred range includes either or both of the upper and lower limits, the range excluding either or both of those included upper and lower limits is also included in this disclosure.

[0172] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which this disclosure pertains. Any methods and materials similar to or equivalent to those described herein may also be used in the implementation or testing of this disclosure.

[0173] All publications referenced herein are incorporated herein by reference to disclose and describe the methods and / or materials for which the publications are cited.

[0174] As will be apparent to those skilled in the art upon reading the present disclosure, each of the individual embodiments described and illustrated herein has separate components and features, which may be readily separated from or combined with the features of any of several other embodiments without departing from the scope or spirit of the present disclosure. Any recited method may be practiced in the order of events recited or in any other order that is logically possible. The present disclosure is intended to provide support for all such combinations.

[0175] As used herein, "may", "may comprise", "may be", "can", "can comprise" and "can be" all indicate what is envisioned by the inventors to be functional and available as part of the provided subject matter.

[0176] Various abbreviations are listed below. Table 10-1 Table 10-2

[0177] The present invention will now be further described by way of Examples, which are intended to assist those skilled in the art in practicing the present invention and are in no way intended to limit the scope of the present invention. Examples

[0178] This Example describes a study designed to demonstrate the safety, tolerability and preliminary efficacy of obe-cel CAR T cells in patients with severe refractory SLE.

[0179] Conceptually, CAR T cells require only a single dose, possess the potential to expand and persist in vivo, migrate to multiple lymphoid tissues and organs in the recipient, and develop into both effector and memory cell populations; therefore, CAR T cell-based therapies such as obe-cel offer further advantages over antibodies. The longer persistence of obe-cel with its CAT CD19 conjugate offers another advantage when indirectly compared to approved FMC63 CD19 CAR T cells.

[0180] As mentioned above, obe-cel is prepared from enriched autologous T cells transduced using a lentiviral vector to express a novel second-generation CAR that targets CD19 and has a 4-1BB endodomain and a CD3-ζ endodomain.

[0181] The CARs of obe-cel CAR T cells contain a single-stranded variable fragment (scFv) called CAT, which has lower affinity for CD19 and a faster dissociation rate compared to FMC63 scFv used in other approved CD19 CAR T therapies. This binding kinetic with rapid dissociation (-off) is intended to provide opportunities for physiological T cell activation, reduced immunotoxicity, and improved persistence. See WO2016 / 139487.

[0182] Obe-cel is classified as an Advanced Therapeutic Investigational Product (ATIMP). It is an autologous cell therapy product whose active ingredient is patient-derived T cells transduced by a lentiviral vector to express a novel second-generation CAR targeting CD19 (sometimes referred to herein as "CD19 CAT CAR"). Obe-cel also contains untransduced autologous T cells and non-T cells.

[0183] When administered to a patient, obe-cel CAR T cells circulate throughout the body. These CAR T cells recognize the CD19 surface antigen on all B cells and B progenitor cells, which leads to their activation and proliferation. Activated CAR T cells then cause the destruction of these cells through several physiological effector mechanisms.

[0184] (Example 1) Eligibility Criteria Patients treated are those with severe, refractory SLE who, due to disease severity, one or more SLE-associated organ system lesion areas, and prior exposure to multiple SLE treatment strategies, are expected to have inadequate outcomes when treated with standard treatments.

[0185] The patient must meet all eligibility criteria.

[0186] Key inclusion criteria • Diagnosis of systemic lupus erythematosus (SLE) meeting the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria. • Positive for at least one of the following autoantibodies: 1: Antinuclear antibody (ANA) with a titer of 80 or higher, or anti-dsDNA (≧30 IU / mL), anti-Smith (>ULN), anti-histone, or anti-chromatin (>ULN). Severe SLE as defined below: - A Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 8 points or higher (of which 4 are non-laboratory items and points related to neurological findings [SLEDAI 2K items 1-7] are excluded), and - At least one of the following severe SLE-related organ lesions: • Kidney (currently active lupus nephritis, confirmed by biopsy) Note: Biopsies should be performed (unless contraindicated) within 12 months prior to the screening visit or during the screening period to confirm currently active, biopsy-verified lupus nephritis. Histopathological reports should be available as a source. • Moderate or severe pericarditis / myocarditis • Moderate or severe pleurisy or other lung lesions · Vasculitis • Severe hematological symptoms (e.g., severe thrombocytopenia or severe autoimmune hemolytic anemia) • Refractory SLE (defined as lack of response, insufficient response, or persistent lack of response) or intolerance to the following: a. Hydroxychloroquine treatment in combination with corticosteroids, and b. In cases of intolerance, at least two of the following treatment groups are used for at least three months each or less: i. Immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate mofetil, mycophenolate, tacrolimus, leflunomide, cyclosporine, voclosporine, or cyclophosphamide) ii. B-cell targeting agents (e.g., belimumab, anti-CD20 mAb) iii. Cytokine inhibitors (e.g., aniflorumab).

[0187] Key Exclusion Criteria SLE and autoimmune diseases • Recurrent neuropsychiatric lupus at any point prior to the screening visit, or active, severe, or unstable neuropsychiatric lupus within the past two years. • Diagnosis of drug-induced SLE, not idiopathic SLE. • Any acute severe lupus-related relapse during screening that requires immediate treatment and / or makes immunosuppressant washout impossible; this makes the patient ineligible for CD19 CAR T therapy, as determined by the principal investigator or sponsor. • In the opinion of the principal investigator, severe SLE-related organ damage (e.g., end-stage renal failure), which is likely to be irreversible, may reduce the likelihood of CD19 CAR T-cell therapy benefiting patients. • Diagnosis of primary antiphospholipid antibody syndrome. • A clinically significant diagnosis of uveitis. • Diagnosis of other non-SLE autoimmune diseases (e.g., dermatomyositis, polymyositis, scleroderma, rheumatoid arthritis) or other non-SLE autoimmune diseases or overlap syndromes.

[0188] Treatment history 1. The following medical history or presence a. Within 3 months prior to the screening visit • Clinically relevant CNS pathologies such as epilepsy, paresis, aphasia, or stroke. • Evidence of deep vein thrombosis or pulmonary embolism b. At any point prior to the screening visit: severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness or disorder. 2. Clinically significant uncontrolled cardiac disease not caused by SLE (New York Heart Association class III or class IV heart failure, uncontrolled angina, severe uncontrolled cardiac arrhythmia, or electrocardiographic evidence of acute ischemia or grade 3 conduction abnormality, except if the patient has a pacemaker) or a recent cardiac event (within 12 months of screening). 3. Active or uncontrolled fungal, bacterial, viral (including COVID-19) or other infections requiring systemic antibiotics for management. 4. Active or latent hepatitis B or active hepatitis C. 5. Testing for positive results for human immunodeficiency virus, HTLV-1, HTLV-2, or syphilis during screening. 6. A history of malignant neoplasms, except in cases of disease-free status for at least 24 months (basal cell carcinoma in situ or squamous carcinoma in situ or ductal carcinoma in situ breast cancer undergoing hormone therapy is permitted). 7. History of heart, lung, kidney, or liver transplantation, or hematopoietic stem cell transplantation. 8. Pregnant or breastfeeding.

[0189] Laboratory and organ function 9. If the following laboratory criteria are met, the patient is not eligible. a. Neutrophil count <1,000 / μL b. Platelet count <50,000 / μL c. Hemoglobin <7 g / dL for SLE-related hemolytic anemia, or hemoglobin <8 g / dL for all other patients. dB cell agenesis e. Serum alanine aminotransferase / aspartate aminotransferase > 2.5 × ULN f. Total bilirubin > 1.5 × ULN in patients without Gilbert's syndrome, or direct bilirubin > 1 × ULN in patients with Gilbert's syndrome. g. Creatinine clearance (estimated by Cockcroft-Gault) <30 mL / min / 1.73 m 2 h.INR and PTT > 1.5ULN. 10. Left ventricular ejection fraction <45% (or <lower limit of institutional normal range) as confirmed by ECHO. 11. SpO2 < 90% in the absence of oxygen support.

[0190] Drug therapy Prior treatment with anti-CD19 therapy (including bispecific antibodies), adoptive T-cell therapy, or any prior gene therapy product (e.g., CAR T-cell therapy). • Use of anti-CD20 therapy within two months of leukocyte apheresis. • Immunization with a live vaccine or attenuated vaccine within two months of leukocyte apheresis. The following are excluded within 14 days prior to leukocyte apheresis: a. Use of standard antimalarial drugs, including biological agents, immunosuppressive therapy, or immunomodulatory therapy. b. Systemic corticosteroids exceeding 10 mg of prednisone or its equivalent daily. • Any investigational drug within 2 months of leukocyte apheresis or within 5 half-lives (whichever is longer). Note: If the half-life is unknown, consider that a 2-month search period may be necessary.

[0191] General • The presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural / peritoneal / pericardial catheter). Note: Central venous access catheters such as Port-a-Cath or Hickman catheters are acceptable. • Inability to tolerate leukocyte apheresis. • Inability to understand or comply with the safety monitoring requirements of the study, or an inability to complete all study visits or procedures required by the protocol, including follow-up visits. • The existence of any contraindications to cyclophosphamide or fludarabine.

[0192] (Example 2) Leukocyte apheresis and lymphocyte depletion therapy Leukocyte apheresis Prior to leukocyte apheresis, between day 6 and day 8, patients will undergo clinical and laboratory evaluations to confirm that they meet all eligibility criteria. This ensures that appropriate identification and tapering of SLE drug therapy are ensured.

[0193] After the necessary washout is complete, the patient will undergo unstimulated leukocyte apheresis for obe-cel generation. This may require insertion of a central venous access device and is a day-case procedure for collecting only PBMCs.

[0194] Inappropriate leukocyte apheresis If any problems arise with the procedure (i.e., improper cell collection for dose preparation, contamination of leukocyte apheresis material), the patient may undergo repeated leukocyte apheresis if clinically appropriate.

[0195] Bridging therapy If it is necessary to control the disease / symptoms, patients may receive bridging therapy with drug therapies of acceptable standard of care (SOC) for treating SLE.

[0196] Lymphocyte depletion chemotherapy Lymphocyte depletion chemotherapy with fludarabine and cyclophosphamide is recognized as the standard treatment before CAR T cell infusion. CAR T cell clinical data comprehensively demonstrate that fludarabine / cyclophosphamide is required for CAR T cell engraftment, and that CAR T cell engraftment is required for activity against B cells.

[0197] The patient will receive three doses of fludarabine and one dose of cyclophosphamide, as follows: Fludarabine: 25 mg / m² on days -5, -4, and -3. 2 IV administration per day Cyclophosphamide: 1000 mg / m² on day 3 2 IV administration This lymphocyte depletion regimen is consistent with the regimen published by Mackensen et al (2022). If obe-cel injection cannot be performed within 10 days of lymphocyte depletion, lymphocyte depletion therapy can be repeated.

[0198] (Example 3) Obe-cel The starting material for the production of obe-cel is mononuclear cells derived from patient-derived non-mobilized leukocyte apheresis collection. Therefore, obe-cel is an autologous product and thus specific to each patient.

[0199] Autologous T cells were transduced ex vivo using a lentiviral vector to enrich them and express a novel CD19-targeting (i.e., anti-CD19) CAR (referred to as "CD19(CAT)CAR"). The "CAT" binding domain was selected as the binding domain because it showed substantially lower affinity for CD19 (less than 1 / 40th) than FMC63 scFv, a conjugate already used in commercially available CAR T cell therapies.

[0200] More specifically, the CD19(CAT)CAR construct is derived from the mouse CAT13.1E10 hybridoma, and the CAR contains anti-CD19 scFv, CD8-derived stalk and transmembrane domains, and a complex endodomain fusion of a 4-1BB endodomain and a CD3ζ endodomain.

[0201] obe-cel is generated by ex vivo transduction of activated peripheral blood mononuclear cells using a modified HIV-derived lentiviral vector containing a CD19 CAR expression cassette. The lentiviral vector is prepared by cotransfecting HEK293T cells with four plasmids under Good Manufacturing Practice (GMP) conditions, followed by collection and purification of the culture supernatant.

[0202] Cells derived from leukocyte apheresis starting material are enriched by positive selection of CD4+ / CD8+ cells using magnetic beads in a Miltenyi CliniMACS® Prodigy bioreactor. The cells are then washed and stimulated with mitotic ligands and cytokines. One day after activation, the cells are transduced with a lentiviral vector. After transduction, the cells are expanded (active pharmaceutical ingredient) to produce the desired dose. The cells are then washed and formulated using a phosphate-buffered saline (PBS) / ethylenediaminetetraacetic acid (EDTA) / human serum albumin (HSA) / dimethyl sulfoxide (DMSO) buffer, filled into final packaging, and cryopreserved (drug product). The obe-cel product contains transduced and untransduced T cells. The dose administered to the patient is expressed as the total number of CD19 CAR-positive T cells (active ingredient).

[0203] obe-cel is supplied as a cell suspension cryopreserved in a cryopreservation-compatible infusion bag, which is then thawed at 37°C.

[0204] obe-cel dose The selection and rationale for the obe-cel dose are based in part on prior use of obe-cel in patients with B-ALL and other B-cell malignancies.

[0205] To date, obe-cel has been administered to over 200 patients with B-cell malignancies. Various drug administration strategies have been evaluated.

[0206] Relapsing / refractory CD19 + In the central FELIX study in patients with B-ALL, 410 × 10 6The planned total target dose of CAR T cells was administered as divided doses on days 1 and 10, based on the percentage of blast cells in the bone marrow prior to the initiation of lymphocyte depletion chemotherapy (Roddie et al (2021), above; Roddie et al (2023a), above). This drug regimen was safe and effective in such cases where it is difficult to treat patients with relapsed / refractory B-ALL. Importantly, no grade 3 or higher CRS and / or ICANs events were observed in B-ALL patients in complete remission (less than 5% myeloblasts at the initiation of lymphocyte depletion chemotherapy). CRS or ICANs of any grade were observed in 48% and 7%, in that order, respectively.

[0207] However, it is intended herein that the overall number of B cells, including autoreactive B cells, is limited in patients with refractory SLE, in contrast to patients with relapsed / refractory B-ALL who have a much larger number of CD19-positive B lymphoblasts. Therefore, it is intended herein that only much lower doses of obe-cel are required to deplete and reset the B cell compartment in patients with refractory SLE.

[0208] In the initial clinical evaluation of CD19 CAR T treatment in a limited number of SLE patients (Mackensen et al., see above), 1 × 10⁶ per kg of body weight was observed. 6 When administered as a single dose of individual CAR T cells, the cells were well-tolerated and demonstrated promising signs of initial efficacy.

[0209] In this specification, 50 × 10 6 A single dose of (±20%) CD19 CAR-positive viable T cells should be infused to the patient on day 1 after lymphocyte depletion chemotherapy. Any other doses intended should be escalated (100 × 10⁶). 6 [±20%] pieces) or gradually decreasing (30 × 10 6 This is the dose of CAR-positive T cells (±20%).

[0210] Across currently evaluated drug administration strategies, obe-cel demonstrated an acceptable safety profile and significant CAR T expansion across a wide range of patient weights. Compared to the FMC63 CAR T construct used by Mackensen et al (2022), obe-cel has a different mechanism of action, a trend towards a larger AUC, and improved expansion. Based on the above product characteristics and taking into account the effect of CAR T expansion, the impact on safety and efficacy due to variations in patient weight or body surface area is expected to be minimal. 50×10 6 The starting dose of (±20%) CD19 CAR-positive viable T cells is one-eighth of the total obe-cel target dose used in adult B-ALL patients, demonstrating an acceptable safety profile in the B-ALL patient population. The mean (standard deviation) body weight in two large randomized phase 3 belimumab studies totaling 865 SLE patients was 61±13 kg, with the lowest body weight in these studies being 35 kg (US Food & Drug Administration. Arthritis advisory committee meeting briefing document BLA 125370. October 2010), which actually corresponds to 50×10 6 This suggests that a certain dose of CAR-positive T cells (±20%) is intended to be safe and effective.

[0211] (Example 4) Exclusion criteria for obe-cel injection The following are the exclusion criteria for obe-cel injection. 1. Use of any systemic corticosteroid exceeding 10 mg of prednisone or its equivalent daily within 72 hours prior to obe-cel injection. 2. Body temperature above 38°C, unrelated to SLE. 3. Severe complications requiring systemic antibiotics at the time of obe-cel infusion (if severe complications are considered under control, the continuation of systemic antibiotics to complete the treatment course does not constitute a criterion for withholding obe-cel infusion). 4. SpO2 < 90% in the absence of oxygen support at the scheduled time of obe-cel infusion. 5. A persistent non-hematological adverse event that has not recovered to baseline or grade 2 or lower due to any cause. 6. Ongoing therapeutic anticoagulation. 7. Uncontrolled cardiac arrhythmia.

[0212] (Example 5) Obe-cel injection and evaluation of disease activity and response to treatment. The patient receives a single dose of (IV) obe-cel intravenously on days -2 and -1, following a two-day rest period after lymphocyte depletion.

[0213] Obe-cel is administered via IV infusion on day 1. Briefly, obe-cel is thawed in a 37°C water bath under sterile conditions. Obe-cel is administered as an IV infusion over several minutes (up to 30 minutes after thawing to preserve cell viability) via a central or peripheral venous line using a syringe or gravity-assisted infusion through an 18-gauge blood set.

[0214] Assessment of disease activity and response to treatment includes the following: [Table 6-1] [Table 6-2] [Table 7]

[0215] (Example 6) A single-arm, open-label phase I study to determine the safety, tolerability, and preliminary efficacy of obekabutagen autolucel (obe-cel) in patients with severe, refractory systemic lupus erythematosus (SLE). Research design / explanation The participants were 50 x 10 6 It is expected that (±25%) of the cells will receive a single infusion of obe-cel at the target dose.

[0216] The primary endpoint is the percentage of participants who achieve a CRR (Continued Clinical Response Rate) 12 months after obe-cel injection, as determined by the Independent Response Review Committee (IRRC).

[0217] Following day 1 (infusion day), safety monitoring for at least 10 days post-infusion is required, with a particular focus on identifying signs and symptoms indicating potential CAR T cell-specific adverse events, through daily contact from the site's clinical team and site visits as per SoA. After the 10-day post-infusion safety monitoring period, participants will be followed up with daily to every 3 days contact from the site's clinical research team, as well as outpatient site visits on days 15, 22, 25, and 28. If a fever of 38°C or higher or changes in neurological behavior occur, the principal investigator must be called immediately, and the participant may be readmitted to the hospital.

[0218] Based on newly emerging data, the study may be terminated due to insufficient response or excessive treatment toxicity.

[0219] The study includes three periods: 1. Screening period: From day 30 to registration day a. Screening: After obtaining informed consent, participants will undergo screening procedures to confirm that they are eligible for the study and can undergo leukocyte apheresis. b. Leukocyte apheresis: Eligible participants will proceed to leukocyte apheresis to collect mononuclear cells to be used in the production of obe-cel. c. Enrollment: Participants will be enrolled in the study once they meet all eligibility criteria and their leukocyte apheresis material is approved for production. 2. Treatment period: From the registration date to day 1 until the end of treatment (EOT) / day 1. a. Lymphocyte depletion (LD) assessment: Participants will be assessed from day -8 to day -6 to determine their eligibility to initiate LD. b. LD chemotherapy: Participants will receive intravenous (iv) fludarabine and cyclophosphamide for LD to enhance treatment efficacy and CD19 CAR T cell survival. • Fludarabine: 25 mg / m² on days -5, -4, and -3 2 / day (iv). • Cyclophosphamide: 1,000 mg / m² on day 3 2 (iv). • Washout over 48 hours, from day -2 to day -1. Note: Day 0 does not exist. After day -1, the next step is the infusion, which is defined as day 1. c. Dosage: If a participant's eligibility to receive the infusion is confirmed, the participant will receive a single infusion on Day 1. Note: EOT is defined as the infusion day (Day 1), or, if it is before the infusion, as the early study termination day. 3. Post-treatment period: From day 1 until the end of the study (EOS). Efficacy and safety follow-up: a. After the infusion, all participants will be closely monitored for safety and efficacy. The first efficacy assessment will be performed on day 28 after the infusion. b. Participants will then be followed up until End of Service (EOS) with monthly or quarterly assessments of safety, tolerability, and efficacy. c. Following the 24-month visit, participants will be followed every three months until the last participant's last visit (LPLV) for this study is completed (i.e., when the last enrolled participant reaches 24 months). The final three-month follow-up assessment prior to the LPLV will be to determine the End of Study (EOS) date for each individual participant. d. EOS is defined as the completion of the LPLV for this study.

[0220] Key inclusion criteria Participants must be between 16 and 65 years of age (inclusive) at the time they sign the informed consent form. • Diagnosis of SLE that meets the 2019 European League Against Rheumatism / American College of Rheumatology classification criteria. • Positive for at least one of the following autoantibodies: 1: ANA with a titer of 80 or higher, or anti-dsDNA (≥30 IU / mL), or anti-Smith (>upper limit of normal [ULN]), anti-histone, or anti-chromatin (>ULN). Severe active SLE is defined as follows: ○ ASLEDAI-2K score of 8 points or higher (of which 4 are non-laboratory items, and points related to neurological findings [ASLEDAI 2K items 1-7] are excluded), and • Severe active LN as defined below: ○ SLE-related renal lesions. Biopsies must be performed within six months prior to the screening visit or during the screening period to confirm active LN or active / chronic LN of currently active class III, class IV, or class V (V only when combined with class III or class IV), in accordance with the 2019 International Society of Nephrology / Renal Pathology Society standards for renal biopsy evidence. ○ UPCR exceeding 1 mg / mg from 24-hour urine collection, and 30 mL / min / 1.73 m 2 The above eGFR • Refractory SLE (defined as a lack of response, insufficient response, or persistent lack of response or intolerance to such drugs, and for which further use is not permitted): a. Hydroxychloroquine in combination with corticosteroids, and b. For two or more of the following treatment groups used over a period of at least six months: i. Immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate mofetil, mycophenolate, leflunomide, or cyclophosphamide). ii. Calcineurin inhibitors (e.g., cyclosporine, voclosporine, tacrolimus). iii. B-cell targeting agents (e.g., belimumab, anti-CD20 mAb) or cytokine inhibitors (e.g., aniflorumab).

[0221] Key Exclusion Criteria • Recurrent neuropsychiatric lupus at any point in time prior to screening, or active, severe, or unstable neuropsychiatric lupus within one year of screening. • Two or more acute severe lupus-related relapses during screening that require immediate treatment and / or make immunosuppressant washout impossible; this makes the participant ineligible for CD19 CAR T therapy (one relapse treatment is acceptable and the participant must be thoroughly rescreened; such cases should be discussed with the medical monitor). • In the opinion of the principal investigator, severe, irreversible SLE-related organ damage (e.g., ESRD) is likely to reduce the likelihood of CD19 CAR T cell-based gene therapy benefiting participants. • A clinically significant diagnosis of uveitis • Participants are ineligible if any of the following laboratory criteria are met. Note: If one or more laboratory parameters do not meet the eligibility requirements, this can be repeated once within the 30-day screening period. - Neutrophil count <1,000 / μL. - Platelet count <50,000 / μL. Hemoglobin <7 g / dL for SLE-related hemolytic anemia, or <8 g / dL for all other participants. - B cell agenesis. - Serum alanine aminotransferase / aspartate aminotransferase > 2.5 × ULN. - Total bilirubin > 1.5 × ULN in participants without Gilbert's syndrome, or direct bilirubin > 1 × ULN in participants with Gilbert's syndrome. - International standardized ratio and activated partial thromboplastin coagulation time > 1.5 ULN.

[0222] Table 8 lists the prohibited and permitted drug therapies. [Table 8] [Table 9-1] [Table 9-2]

[0223] (Example 7) A single-arm, open-label phase I study to determine the safety, tolerability, and preliminary efficacy of obekabutagen autolucel (obe-cel) in patients with severe, refractory systemic lupus erythematosus (SLE): Outcomes of the first treated patient. A 32-year-old female SLE patient was treated with obe-cel. This patient was a Black or African American diagnosed with SLE in 2021, with a history of renal (LN class IV / V), musculoskeletal, cutaneous, and immune system lesions and hypertension. At screening, she had ANA, anti-dsDNA, anti-Smith, anti-RBP, anti-chromatin autoantibodies, and a SLEDAI-2K score of 24. Prior SLE treatment included hydroxychloroquine, corticosteroids, mycophenolate, rituximab, and obinutuzumab. Following tapering of these immunosuppressants, this patient received 50 × 10⁶ doses on day 1 after lymphocyte depletion chemotherapy. 6 A single dose of (±20%) CD19 CAR-positive viable T cells was administered. Methylprednisolone was used as bridging therapy.

[0224] Effectiveness At the 2-month follow-up, this patient showed clear signs of treatment effectiveness with obe-cel: • Anti-dsDNA: Decreased from over 300 at screening to 40.6; • Proteinuria improved; • The complement system returned to normal. • Serum creatinine level was 4.6 mg / dL; • IgG levels decreased from 6.07 at screening to 2.39 on day 28. IgA decreased from 1.84 to 0.46, and IgM decreased from 0.53 to 0.12. • The SLEDAI-2K score decreased from 24 at screening to less than 2 at 2 months (Figure 1); and · B cell agenesis.

[0225] safety Prior to the infusion, the patient suffered a Grade 3 serious adverse event (SAE), namely an infectious abscess of the left sternocleidomastoid muscle. Neither CRS nor ICANS were observed after the injection. After obe-cel injection, the patient exhibited the following SAE: • Grade 2 CMV reactivation, which was treated with valganciclovir; • Grade 3 malignant hypertension; • Grade 3 neutropenia, suspected to be secondary to valganciclovir. The new drug therapies administered were acyclovir and G-CSF.

[0226] CAR-T cell expansion CD19 CAR-T cells (obe-cel) showed good expansion with a peak at 10 days post-CAR-T cell injection, as indicated by flow cytometry and ddPCR, as shown in the order of Figures 2a and 2b, respectively.

[0227] This patent application claims the benefits of UK Application No. 2316183.9 filed on 23 October 2023, UK Application No. 2404412.5 filed on 27 March 2024, UK Application No. 2412689.8 filed on 29 August 2024, and UK Application No. 2414148.3 filed on 26 September 2024. These applications are incorporated herein by reference in their entirety.

[0228] All publications referenced in the above specification are incorporated herein by reference. Various modifications and variations of the methods and systems described in the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in relation to specific preferred embodiments, it should be understood that the claimed invention should not be excessively limited to such specific embodiments. In fact, various modifications of the described modes for carrying out the invention, which will be apparent to those skilled in the art of molecular biology, CAR technology, or related fields, are intended to be within the scope of the appended claims.

Claims

1. A method for treating an autoimmune disease in a patient, comprising the step of administering cells containing a chimeric antigen receptor (CAR) to the patient, wherein the CAR is a) The following sequence: CDR1 - GYAFSSS (Sequence ID 1), CDR2 - YPGDED (Sequence ID 2) and CDR3 - SLLYGDYLDY (Sequence ID 3) A heavy chain variable region (VH) having a complementarity-determining region (CDR) having a sequence having, and b) The following sequence: CDR1 - SASSSVSSYMH (Sequence ID 4), CDR2-DTSKLAS (SEQ ID NO: 5) and CDR3 - QQWNINPLT (Sequence ID 6) A light chain variable region (VL) having a CDR having a sequence having A method including a CD19 binding domain.

2. The method according to claim 1, wherein the autoimmune disease is systemic lupus erythematosus (SLE).

3. The method according to claim 2, wherein the autoimmune disease is severe SLE.

4. The method according to claim 2, wherein the autoimmune disease is refractory SLE.

5. The method according to any one of the preceding claims, wherein the cells are autologous peripheral blood T cells transduced ex vivo to express the CAR.

6. 50 x 10 6 The method according to any of the preceding claims, wherein a dose of (±20%) CD19 CAR-positive viable T cells is administered to the patient.

7. 100 x 10 6 The method according to any of the preceding claims, wherein a dose of (±20%) CD19 CAR-positive viable T cells is administered to the patient.

8. 30 x 10 6 The method according to any of the preceding claims, wherein a dose of (±20%) CD19 CAR-positive viable T cells is administered to the patient.

9. The method according to any of the preceding claims, wherein the administration is by intravenous injection.

10. The method according to any of the preceding claims, wherein the CD19 binding domain comprises a VH domain having the sequence shown as SEQ ID NO: 7 and / or a VL domain having the sequence shown as SEQ ID NO: 8, or a variant of either having at least 95% sequence identity.

11. The method according to claim 10, wherein the CD19 binding domain comprises scFv in a VH-VL orientation.

12. The method according to claim 11, wherein the CD19 binding domain comprises the scFv sequence shown as Sequence ID No. 9, or a variant thereof having at least 90% sequence identity.

13. The method according to any of the preceding claims, wherein the CAR includes a CD8 stork spacer.

14. The method according to any prior claim, wherein the CAR comprises an intracellular T cell signaling domain comprising a 41BB end domain and a CD3-zeta end domain.

15. A method for treating autoimmune diseases in patients, 50 x 10 6 A method comprising the step of administering to the patient a dose of (±20%) CD19 CAR-positive viable T cells.

16. A method for treating autoimmune diseases in patients, 30 x 10 6 A method comprising the step of administering to the patient a dose of (±20%) CD19 CAR-positive viable T cells.

17. A method for treating autoimmune diseases in patients, 100 x 10 6 A method comprising the step of administering to the patient a dose of (±20%) CD19 CAR-positive viable T cells.

18. The method according to claims 15 to 17, wherein the autoimmune disease is SLE.

19. The method according to claim 18, wherein the autoimmune disease is severe SLE.

20. The method according to claim 18, wherein the autoimmune disease is refractory SLE.

21. The method according to claims 18 to 20, wherein the SLE presents with active lupus nephritis.